AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
AAPL   318.75 (+0.16%)
FB   225.05 (-0.18%)
AMZN   2,414.63 (+0.56%)
NVDA   344.11 (+1.36%)
CGC   17.25 (-20.58%)
BABA   199.12 (-0.19%)
MU   46.71 (+0.52%)
TSLA   812.74 (+0.86%)
AMD   52.39 (+1.24%)
T   30.70 (-1.16%)
GILD   75.38 (+0.08%)
DIS   114.99 (-1.51%)
BAC   24.54 (-1.29%)
BA   145.11 (-3.14%)
Log in

NASDAQ:ATECAlphatec Stock Price, Forecast & News

$4.45
+0.05 (+1.14 %)
(As of 05/29/2020 11:36 AM ET)
Add
Compare
Today's Range
$4.33
Now: $4.45
$4.47
50-Day Range
$3.53
MA: $4.20
$4.91
52-Week Range
$2.19
Now: $4.45
$7.93
Volume7,321 shs
Average Volume369,190 shs
Market Capitalization$282.17 million
P/E RatioN/A
Dividend YieldN/A
Beta1.97
Alphatec Holdings, Inc., a medical technology company, focuses on the design, development, and promotion of products for the surgical treatment of spine disorders. Its product portfolio and pipeline address the cervical, thoracolumbar, and intervertebral regions of the spine; and cover various spinal disorders and surgical procedures. The company offers MIS products consisting of Battalion Lateral Spacer System and Squadron Lateral Retractor, Illico Minimally Invasive Surgery System, and BridgePoint Spinous Process Fixation System; and fixation products, such as Arsenal Screw System and Zodiac Spinal Fixation Systems. It also provides cervical and cervico-thoracic products, including Trestle Luxe Anterior Cervical Plate System, and Solanas Posterior Cervico/Thoracic Fixation System and Avalon Occipital Plate; and interbody Systems, such as Battalion Universal Spacer System, Novel PEEK and Titanium Spinal Spacers, and Alphatec Solus Locking ALIF Spinal Spacer. In addition, the company offers biologics consisting of AlphaGraft Structural Allograft Spacers, AlphaGraft ProFuse Demineralized Bone Scaffold, Amnioshield Amniotic Tissue Barrier, Alphagraft Demineralized Bone Matrix, and Neocore Osteoconductive Matrix. It sells its products through a network of independent distributors and direct sales representatives in the United States. Alphatec Holdings, Inc. was founded in 1990 and is headquartered in Carlsbad, California.
Read More
Alphatec logo

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 1.9Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.41 out of 5 stars


Industry, Sector and Symbol

Industry Surgical & medical instruments
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:ATEC
CUSIP02081G10
Phone760-431-9286

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$113.43 million
Book Value$0.43 per share

Profitability

Net Income$-57,000,000.00

Miscellaneous

Employees195
Market Cap$282.17 million
Next Earnings Date7/22/2020 (Estimated)
OptionableNot Optionable

Receive ATEC News and Ratings via Email

Sign-up to receive the latest news and ratings for ATEC and its competitors with MarketBeat's FREE daily newsletter.

Alphatec (NASDAQ:ATEC) Frequently Asked Questions

How has Alphatec's stock been impacted by COVID-19 (Coronavirus)?

Alphatec's stock was trading at $4.41 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, ATEC stock has increased by 0.2% and is now trading at $4.42. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Alphatec?

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Alphatec in the last year. There are currently 4 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Alphatec.

When is Alphatec's next earnings date?

Alphatec is scheduled to release its next quarterly earnings announcement on Wednesday, July 22nd 2020. View our earnings forecast for Alphatec.

How were Alphatec's earnings last quarter?

Alphatec Holdings Inc (NASDAQ:ATEC) announced its quarterly earnings results on Monday, May, 11th. The medical technology company reported ($0.33) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.20) by $0.13. The medical technology company had revenue of $30.12 million for the quarter, compared to the consensus estimate of $29.82 million. Alphatec had a negative return on equity of 167.29% and a negative net margin of 54.42%. View Alphatec's earnings history.

What guidance has Alphatec issued on next quarter's earnings?

Alphatec issued an update on its first quarter 2020 Pre-Market earnings guidance on Wednesday, April, 8th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $29.6-30 million, compared to the consensus revenue estimate of $29.93 million.

What price target have analysts set for ATEC?

4 brokerages have issued 12-month price objectives for Alphatec's stock. Their forecasts range from $7.00 to $15.00. On average, they expect Alphatec's share price to reach $9.63 in the next year. This suggests a possible upside of 117.8% from the stock's current price. View analysts' price targets for Alphatec.

Has Alphatec been receiving favorable news coverage?

Press coverage about ATEC stock has been trending somewhat negative this week, according to InfoTrie Sentiment. InfoTrie ranks the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of publicly-traded companies on a scale of -5 to 5, with scores closest to five being the most favorable. Alphatec earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media stories about the medical technology company a news buzz of 10.0 out of 10, indicating that recent press coverage is extremely likely to have an effect on the company's share price in the near future. View the latest news aboutAlphatec.

Are investors shorting Alphatec?

Alphatec saw a decline in short interest in the month of April. As of April 15th, there was short interest totaling 3,030,000 shares, a decline of 8.7% from the March 31st total of 3,320,000 shares. Based on an average trading volume of 661,000 shares, the days-to-cover ratio is presently 4.6 days. Currently, 6.8% of the company's shares are sold short. View Alphatec's Current Options Chain.

Who are some of Alphatec's key competitors?

What other stocks do shareholders of Alphatec own?

Who are Alphatec's key executives?

Alphatec's management team includes the following people:
  • Mr. Patrick S. Miles, Exec. Chairman & CEO (Age 53)
  • Mr. Craig E. Hunsaker, Exec. VP of People & Culture, Corp. Sec. and Gen. Counsel (Age 55)
  • Mr. Terry M. Rich, Consultant (Age 51)
  • Mr. Jeffrey P. Rydin, Director (Age 52)
  • Mr. Jeffrey G. Black, Exec. VP & CFO (Age 50)

What is Alphatec's stock symbol?

Alphatec trades on the NASDAQ under the ticker symbol "ATEC."

Who are Alphatec's major shareholders?

Alphatec's stock is owned by many different institutional and retail investors. Top institutional shareholders include Driehaus Capital Management LLC (2.98%), Penn Capital Management Co. Inc. (2.32%), New York State Common Retirement Fund (1.01%), Geode Capital Management LLC (0.93%), Morgan Stanley (0.85%) and JPMorgan Chase & Co. (0.76%). Company insiders that own Alphatec stock include Craig E Hunsaker, David Sponsel, Evan Bakst, James L L Tullis, Jeffrey G Black, Jeffrey P Rydin and Kelli Mari Howell. View institutional ownership trends for Alphatec.

Which major investors are selling Alphatec stock?

ATEC stock was sold by a variety of institutional investors in the last quarter, including Parametric Portfolio Associates LLC, Bank of New York Mellon Corp, Deutsche Bank AG, Russell Investments Group Ltd., UBS Group AG, Mesirow Financial Investment Management Inc., Essex Investment Management Co. LLC, and Falcon Point Capital LLC. Company insiders that have sold Alphatec company stock in the last year include Craig E Hunsaker, James L L Tullis, Jeffrey G Black, and Jeffrey P Rydin. View insider buying and selling activity for Alphatec.

Which major investors are buying Alphatec stock?

ATEC stock was acquired by a variety of institutional investors in the last quarter, including Penn Capital Management Co. Inc., New York State Common Retirement Fund, Morgan Stanley, JPMorgan Chase & Co., Mercer Global Advisors Inc. ADV, Driehaus Capital Management LLC, Perkins Capital Management Inc., and Geode Capital Management LLC. Company insiders that have bought Alphatec stock in the last two years include David Sponsel, Evan Bakst, and Kelli Mari Howell. View insider buying and selling activity for Alphatec.

How do I buy shares of Alphatec?

Shares of ATEC can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Alphatec's stock price today?

One share of ATEC stock can currently be purchased for approximately $4.42.

How big of a company is Alphatec?

Alphatec has a market capitalization of $280.27 million and generates $113.43 million in revenue each year. The medical technology company earns $-57,000,000.00 in net income (profit) each year or ($1.09) on an earnings per share basis. Alphatec employs 195 workers across the globe.

What is Alphatec's official website?

The official website for Alphatec is www.atecspine.com.

How can I contact Alphatec?

Alphatec's mailing address is 5818 EL CAMINO REAL, CARLSBAD CA, 92008. The medical technology company can be reached via phone at 760-431-9286 or via email at [email protected]

This page was last updated on 5/29/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.